# Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors

> **NCT07368153** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 9 (estimated)

## Conditions studied

- EBV Infections
- Kidney Transplant

## Interventions

- **DRUG:** indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07368153
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07368153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07368153, "Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07368153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*